DiscoverThe Readout Loud376: BridgeBio’s great week and Moderna’s unraveling
376: BridgeBio’s great week and Moderna’s unraveling

376: BridgeBio’s great week and Moderna’s unraveling

Update: 2025-10-30
Share

Description

Has BridgeBio’s business model worked? How are executives at Moderna dealing with the company’s slump? And who will the hosts dress up as for Halloween?



We discuss all that on this week’s episode of the “The Readout LOUD,” STAT’s biotech podcast. We bring on BridgeBio CEO Neil Kumar to discuss the company’s positive Phase 3 readouts and our colleague Jason Mast to discuss Moderna’s struggles following its Covid-19 vaccine boom.

Comments 
loading
In Channel
380: A new top drug regulator and the future of psychedelics

380: A new top drug regulator and the future of psychedelics

2025-12-0432:45

379: How Mark Cuban plans to ‘f— up’ health care

379: How Mark Cuban plans to ‘f— up’ health care

2025-11-2036:44

378: Merck's heart disease win and the FDA's new drug regulator

378: Merck's heart disease win and the FDA's new drug regulator

2025-11-1335:40

377: Melodrama at the FDA and the Pfizer-Novo bidding war

377: Melodrama at the FDA and the Pfizer-Novo bidding war

2025-11-0630:55

376: BridgeBio’s great week and Moderna’s unraveling

376: BridgeBio’s great week and Moderna’s unraveling

2025-10-3037:58

375: Startups push the FDA and biotech booms in North Carolina

375: Startups push the FDA and biotech booms in North Carolina

2025-10-2328:58

374: Veteran biotech executive Clive Meanwell on drug pricing and the obesity market

374: Veteran biotech executive Clive Meanwell on drug pricing and the obesity market

2025-10-1633:56

373: Party in biotech land and AstraZeneca’s miscalculation

373: Party in biotech land and AstraZeneca’s miscalculation

2025-10-0945:40

372: A pharma C-suite shakeup and Trump's deal with Pfizer

372: A pharma C-suite shakeup and Trump's deal with Pfizer

2025-10-0227:51

371: A gene therapy success in Huntington's and Trump's autism announcement

371: A gene therapy success in Huntington's and Trump's autism announcement

2025-09-2542:18

370: Pharma sours on the U.K., plus biotech M&A's quiet roll

370: Pharma sours on the U.K., plus biotech M&A's quiet roll

2025-09-1837:21

369: Trump, Chinese biotech, and an industry career reshaped by illness

369: Trump, Chinese biotech, and an industry career reshaped by illness

2025-09-1136:19

368: New stakes in the vaccine dispute and a boost for biotech

368: New stakes in the vaccine dispute and a boost for biotech

2025-09-0427:02

367: The ouster of CDC's director, biotech venture firm rankings

367: The ouster of CDC's director, biotech venture firm rankings

2025-08-2827:35

366: Viking’s obesity flop, ‘pharma to table’ drug sales

366: Viking’s obesity flop, ‘pharma to table’ drug sales

2025-08-2125:28

365: Vinay Prasad’s return, animal testing alternatives, and mRNA upended

365: Vinay Prasad’s return, animal testing alternatives, and mRNA upended

2025-08-1427:15

364: Closing a zombie biotech, and Lilly's disappointing obesity readout

364: Closing a zombie biotech, and Lilly's disappointing obesity readout

2025-08-0736:55

363: What Vinay Prasad’s ouster means for biotech and the FDA

363: What Vinay Prasad’s ouster means for biotech and the FDA

2025-07-3143:52

362: A mother’s perspective on Sarepta’s gene therapy halt

362: A mother’s perspective on Sarepta’s gene therapy halt

2025-07-2436:25

361: Inside an FDA drug rejection, and layoffs at Sarepta

361: Inside an FDA drug rejection, and layoffs at Sarepta

2025-07-1742:31

loading
Google Play
Download from Google Play
Castbox
Download from App Store
usUnited States
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

376: BridgeBio’s great week and Moderna’s unraveling

376: BridgeBio’s great week and Moderna’s unraveling

STAT